Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Y M RustumS Seeber

Abstract

Although fluoropyrimidines, in particular, fluorouracil (5-FU) and fluorodeoxyuridine (FdUrd), are active alone and in combination with other agents in a variety of human malignancies, therapeutic selectivity, resistance, and efficacy have been a major limitation in cancer therapy. Preclinical and clinical results in advanced and adjuvant colorectal cancers confirmed that the therapeutic efficacy of fluoropyrimidines, with thymidylate synthase (TS) as a primary target, can be improved significantly with leucovorin (LV) modulation. With the recognition that TS is an important therapeutic target, direct and specific inhibitors have been developed and are under intensive preclinical and clinical evaluation, primarily in patients with colorectal cancer, with demonstrable activity. The direct TS inhibitors have been shown to be potent, with a high level of specificity under therapeutic conditions for TS. This includes ZD1694, AG337, and LY231514. To date, although the therapeutic activity of both direct and indirect inhibitors of TS is similar, differences in the magnitude and profile of toxicity have been observed. A phase III comparative evaluation of a direct inhibitor of TS (ZD1694) with an indirect inhibitor (5-FU/LV) has been ...Continue Reading

Citations

Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U VanhoeferH Wilke
Nov 24, 1999·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·A S HaqqaniH C Birnboim
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U VanhoeferY M Rustum
Aug 17, 2004·International Journal of Colorectal Disease·R BrollU Windhövel
Jul 18, 2006·British Journal of Clinical Pharmacology·Wei Peng YongMark J Ratain
Feb 14, 2012·Expert Opinion on Investigational Drugs·M MorottiS Ferrero
Nov 25, 2003·Journal of Clinical Pharmacy and Therapeutics·K BezulierY Barra
Nov 4, 2000·Expert Opinion on Investigational Drugs·R L Schilsky, H L Kindler
Mar 28, 2006·Future Oncology·Cheng-Long HuangMoritoshi Kinoshita
Apr 23, 2005·Japanese Journal of Clinical Oncology·Sang Hoon JiKeunchil Park
Nov 13, 2003·Expert Opinion on Emerging Drugs·Lucy ScottJim Cassidy
Jul 13, 2005·Cancer Chemotherapy and Pharmacology·Olaf H TemminkGodefridus J Peters
Jun 11, 2011·The Oncologist·Maarten J DeenenJan H M Schellens
Sep 21, 2017·Oncology Letters·Leanne Lee LeungJames Chung-Man Ho
May 23, 2000·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·B Van TriestG J Peters
Jul 31, 2002·The Journal of Biological Chemistry·Hisaya KawateLawrence A Loeb
Aug 24, 2000·International Journal of Cancer. Journal International Du Cancer·H H BackusG J Peters
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C AscheleA Sobrero
Feb 21, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Y F LiJ J Kavanagh
Nov 25, 2003·Hematology·William L CarrollJohn C Reed
Jan 5, 2001·Expert Opinion on Investigational Drugs·R Pazdur, M E Royce
Jun 11, 2008·Nature Clinical Practice. Oncology·Bruno VincenziGiuseppe Tonini
Oct 18, 2011·Expert Review of Anticancer Therapy·Veerle F Surmont, Jan P van Meerbeeck
Sep 29, 2011·Clinical Chemistry and Laboratory Medicine : CCLM·Thomas I Peng SohFederico Innocenti
Jan 15, 2003·Annual Review of Medicine·R NagasubramanianM J Ratain
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J J RusthovenJ Iglesias
Jul 5, 2005·Expert Opinion on Investigational Drugs·E Van Cutsem
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·H L McLeod, W E Evans
Jul 23, 1999·Current Opinion in Oncology·M E Royce, R Pazdur

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.